Bumetanide Nasal Spray: First Approval
Clinical Drug Investigation · 2026-02 · 46 (2) · 237-240
DOI: 10.1007/s40261-025-01503-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Drug Investigation, online erschienen am 12.11.2025. Verfasst von Hannah A Blair. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. cdi@adis.com. Hauptthemen laut MEDLINE: Bumetanide, Edema, Sodium Potassium Chloride Symporter Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Bumetanide nasal spray (ENBUMYST™) is a loop diuretic developed by Corstasis Therapeutics for the treatment of oedema. It is designed as a short-term therapeutic option, with absorption via the nasal mucosa potentially offering more consistent or predictable bioavailability than oral administration, particularly in patients with gastrointestinal impairment. Bumetanide nasal spray received its first approval on 12 September 2025 in the USA for the treatment of oedema associated with congestive heart failure (CHF), and hepatic and renal disease, including nephrotic syndrome in adults. This article summarizes the milestones in the development of bumetanide nasal spray leading to this first approval for the treatment of oedema.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. cdi@adis.com.
Zitieren
APA
Blair, H. A. (2026). Bumetanide Nasal Spray: First Approval. Clinical Drug Investigation, 46(2), 237-240. https://doi.org/10.1007/s40261-025-01503-1
Vancouver
Blair HA. Bumetanide Nasal Spray: First Approval. Clinical Drug Investigation. 2026;46(2):237-240. doi:10.1007/s40261-025-01503-1
BibTeX
@article{Blair2026,
author = {Blair, Hannah A},
title = {Bumetanide Nasal Spray: First Approval},
journal = {Clinical Drug Investigation},
year = {2026},
volume = {46},
number = {2},
pages = {237--240},
doi = {10.1007/s40261-025-01503-1}
}
EUVIMED